Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Merrimack Pharmaceuticals Inc patents


Recent patent applications related to Merrimack Pharmaceuticals Inc. Merrimack Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Merrimack Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Merrimack Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merrimack Pharmaceuticals Inc-related inventors


Combination cancer therapies

The disclosure provides methods of treatment for cancer in patients using bispecific anti-igf-1r, anti-erbb3 antibodies in combination with one or more therapeutic agents that impede regulatory t-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human pd-l1.. ... Merrimack Pharmaceuticals Inc

Combination therapies comprising anti-erbb3 agents

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a mek/pi3 kinase/akt inhibitor; iv) an effective amount of mm-151; v) an effective amount of an mtor inhibitor; and/or vi) an effective amount of trastuzumab or t-dm 1, and/or combinations thereof; and an effective amount of a 10 bispecific anti-erbb2/anti-erbb3 antibody.. ... Merrimack Pharmaceuticals Inc

Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies

Provided are methods for the administration of therapeutic bispecific anti-igf-1r and anti-erbb3 antibodies, either alone or in combination with other anti-cancer therapeutics.. . ... Merrimack Pharmaceuticals Inc

Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions

Epha2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an epha2 targeting moiety (e.g., a scfv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. ... Merrimack Pharmaceuticals Inc

Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands

Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-egfr monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.. . ... Merrimack Pharmaceuticals Inc

Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents

Methods for providing treatment of pathologic conditions with nanoparticulate therapeutic agents are disclosed. Novel methods for determining liposomal deposition at sites of pathology using non-invasive imaging are also disclosed.. ... Merrimack Pharmaceuticals Inc

Bi-specific fusion proteins

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.. ... Merrimack Pharmaceuticals Inc

Cartilage-binding fusion proteins

Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided.. ... Merrimack Pharmaceuticals Inc

Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response

The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a network activation state (nas) or a network inhibition state (nis) for the cells using a computational model of the cellular network. ... Merrimack Pharmaceuticals Inc

Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers

Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an erbb3 inhibitor, e.g., an anti-erbb3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an erbb3 inhibitor, e.g., an anti-erbb3 antibody. ... Merrimack Pharmaceuticals Inc

Dosage and administration of anti-egfr therapeutics

Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-egfr therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-egfr therapy are disclosed.. . ... Merrimack Pharmaceuticals Inc

Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof

Provided by the present disclosure are antibodies (e.g., scfvs) that include cdrs and human framework regions that confer useful properties upon the antibodies. In certain embodiments, such properties include thermostability (e.g., increased melting temperature), efficient binding to staphylococcus aureus protein a, or both. ... Merrimack Pharmaceuticals Inc

Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an erbb3 inhibitor (e.g., an anti-erbb3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an erbb3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. ... Merrimack Pharmaceuticals Inc

Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies

Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with her2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-her2 antibody that is not an inhibitor of her2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-her2 antibody.. ... Merrimack Pharmaceuticals Inc

09/07/17 / #20170253662

Dosage and administration of anti-egfr therapeutics

Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-egfr therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-egfr therapy are disclosed.. . ... Merrimack Pharmaceuticals Inc

08/17/17 / #20170233491

Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment

Disclosed herein are methods of treating pancreatic cancer in a human patient by co-administering istiratumab in combination with gemcitabine and nab-paclitaxel, and dosage regimens for the same.. . ... Merrimack Pharmaceuticals Inc

08/17/17 / #20170231911

Methods and compositions for improving outcomes of liposomal chemotherapy

Materials and methods for treating cancer patients with immunoliposomal chemotherapeutic agents are disclosed. The methods comprise administering to a patient a therapeutically effective amount of an immunoliposome in combination with a chemotherapeutic agent comprising an alkylating agent or an organoplatinum agent. ... Merrimack Pharmaceuticals Inc

08/03/17 / #20170218028

Tandem fc bispecific antibodies

Provided herein are tandem fcs and tandem fc antibodies (“tfcas”), e.g., tandem fc bispecific antibodies (“tfcbas”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a tfc, which tfc comprises a first fc region and a second fc region, wherein the first and the second fc regions are linked through a tfc linker to form a contiguous polypeptide and dimerize to form an fc dimer. ... Merrimack Pharmaceuticals Inc

07/27/17 / #20170210810

Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an erbb3 inhibitor (e.g., an anti-erbb3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an erbb3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. ... Merrimack Pharmaceuticals Inc

07/27/17 / #20170210809

Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses thereof

Disclosed are bispecific binding agents that specifically target both of the igf-1 and the erbb intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-igf-1r antibody and an anti-erbb3 antibody connected by a linker are described herein. ... Merrimack Pharmaceuticals Inc

07/20/17 / #20170204192

Human serum albumin linkers and conjugates thereof

Disclosed is a human serum albumin (hsa) linker and hsa linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the hsa linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain fv molecules (scfvs). ... Merrimack Pharmaceuticals Inc

07/20/17 / #20170202840

Treatment of pancreatic cancer with liposomal irinotecan

A liposome-encapsulated formulation of irinotecan can be used for the treatment of pancreatic cancer in combination with 5-fluorouracil and leucovorin, including treatment of patients diagnosed with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine.. . ... Merrimack Pharmaceuticals Inc

07/06/17 / #20170189335

Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Methods for determining dosage of her2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with her2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.. ... Merrimack Pharmaceuticals Inc

06/01/17 / #20170151226

Treatment of breast cancer with liposomal irinotecan

Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (mm-398). The breast cancer may be triple negative breast cancer (tnbc), estrogen receptor/progesterone receptor (er/pr) positive breast cancer, er-positive breast cancer, or pr-positive breast cancer, or metastatic breast cancer.. ... Merrimack Pharmaceuticals Inc

04/27/17 / #20170112950

Compositions and methods for non-invasive imaging

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. ... Merrimack Pharmaceuticals Inc

04/13/17 / #20170101480

Biomarkers for predicting outcomes of cancer therapy with erbb3 inhibitors

Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to erbb3 inhibitors, and methods of treating a cancer patient with targeted therapies.. . ... Merrimack Pharmaceuticals Inc

04/06/17 / #20170096492

Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith

Provided herein are compositions comprising anti-igf-1r, anti-erbb3 bispecific antibodies alone or in combination with other anti-cancer agents. Also provided are methods of treating a subject having cancer and methods for determining whether a patient with cancer is likely to respond to the compositions described herein.. ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170082630

Marker quantitation in single cells in tissue sections

Improved assays incorporating single-cell based image analysis that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.. . ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170081421

Anti-c-met tandem fc bispecific antibodies

Provided herein are tandem fcs and tandem fc antibodies (“tfcas”), e.g., tandem fc bispecific antibodies (“tfcbas”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a tfc, which tfc comprises a first fc region and a second fc region, wherein the first and the second fc regions are linked through a tfc linker to form a contiguous polypeptide and dimerize to form an fc dimer. ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170080087

Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies

Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having her2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-her2 antibody that is not an inhibitor of her2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-her2 antibody.. ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170079914

Liposomes useful for drug delivery

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.. ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170079913

Liposomes useful for drug delivery

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.. ... Merrimack Pharmaceuticals Inc

03/23/17 / #20170079912

Liposomes useful for drug delivery

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.. ... Merrimack Pharmaceuticals Inc

03/16/17 / #20170073427

Antibodies against the ectodomain of erbb3 and uses thereof

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor. ... Merrimack Pharmaceuticals Inc

03/16/17 / #20170071858

Liposomes useful for drug delivery

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.. ... Merrimack Pharmaceuticals Inc

03/09/17 / #20170065578

Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (mm-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (mm-398) is co-administered with 5-fluorouracil and leucovorin.. ... Merrimack Pharmaceuticals Inc

02/23/17 / #20170051063

Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human igf-1r and human erbb3. Exemplary antibodies inhibit signal transduction through either or both of igf-1r and erbb3. ... Merrimack Pharmaceuticals Inc

02/23/17 / #20170049775

Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.. ... Merrimack Pharmaceuticals Inc

02/23/17 / #20170049768

Methods for treating pancreatic cancer using combination therapies

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (mm-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (mm-398) is co-administered with 5-fluorouracil and leucovorin.. ... Merrimack Pharmaceuticals Inc

02/23/17 / #20170049767

Combination therapy for cancer treatment

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a parp inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. ... Merrimack Pharmaceuticals Inc

02/09/17 / #20170035749

Liposomes useful for drug delivery to the brain

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. ... Merrimack Pharmaceuticals Inc

01/26/17 / #20170022290

Combination therapies for treating her2-positive cancers

Methods for treating cancer patients with her2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-her2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-her2 antibody.. ... Merrimack Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merrimack Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merrimack Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###